Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Originally published as JCO Early Release 10.1200/JCO.2005.01.5180 on December 5 2005

Journal of Clinical Oncology, Vol 24, No 2 (January 10), 2006: pp. 268-273
© 2006 American Society of Clinical Oncology.

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Right arrowRights & Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Bachmann, I. M.
Right arrow Articles by Akslen, L. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Bachmann, I. M.
Right arrow Articles by Akslen, L. A.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Facebook   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

EZH2 Expression Is Associated With High Proliferation Rate and Aggressive Tumor Subgroups in Cutaneous Melanoma and Cancers of the Endometrium, Prostate, and Breast

Ingeborg M. Bachmann, Ole J. Halvorsen, Karin Collett, Ingunn M. Stefansson, Oddbjørn Straume, Svein A. Haukaas, Helga B. Salvesen, Arie P. Otte, Lars A. Akslen

From the the Gade Institute, Section of Pathology; Department of Surgical Sciences, University of Bergen; Department of Clinical Medicine, Section of Obstetrics and Gynecology, Haukeland University Hospital, Bergen, Norway; Department of Biochemistry, Swammerdam Institute for Life Sciences, University of Amsterdam, Amsterdam, the Netherlands

Address reprint requests Lars A. Akslen, MD, PhD, Children’s Hospital, Harvard Medical School, Vascular Biology Program, Karp Family Research Labs 12.125, 300 Longwood Ave, Boston, MA 02115-5737; e-mail: lars.akslen{at}childrens.harvard.edu or lars.akslen{at}gades.uib.no

PURPOSE: EZH2 is a member of the polycomb group of genes and important in cell cycle regulation. Increased expression of EZH2 has been associated previously with invasive growth and aggressive clinical behavior in prostate and breast cancer, but the relationship with tumor cell proliferation has not been examined in human tumors. The purpose of this study was to validate previous findings in a population-based setting, also including tumors that have not been studied previously.

PATIENTS AND METHODS: In our study of nearly 700 patients, we examined EZH2 expression and its association with tumor cell proliferation and other tumor markers, clinical features, and prognosis in cutaneous melanoma and cancers of the endometrium, prostate, and breast.

RESULTS: Strong EZH2 expression was associated with increased tumor cell proliferation in all four cancer types. Associations were also found between EZH2 and important clinicopathologic variables. EZH2 expression showed significant prognostic impact in melanoma, prostate, and endometrial carcinoma in univariate survival analyses, and revealed independent prognostic importance in carcinoma of the endometrium and prostate.

CONCLUSION: Our findings point at EZH2 as a novel and independent prognostic marker in endometrial cancer, and validate previous findings on prostate and breast cancer. Further, EZH2 expression was associated with features of aggressive cutaneous melanoma. The fact that EZH2 might identify increased tumor cell proliferation and aggressive subgroups in several cancers may be of practical interest because the polycomb group proteins have been suggested as candidates for targeted therapy. EZH2 expression should, therefore, be further examined as a possible predictive factor.

Supported by Norwegian Cancer Society, Norwegian Research Council, Meltzer Research Fund, and Helse Vest Research Fund.

Terms in blue are defined in the glossary, found at the end of this article and online at www.jco.org.

Authors’ disclosures of potential conflicts of interest and author contributions are found at the end of this article.


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Facebook Facebook   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
A. G. Muntean and J. L. Hess
Epigenetic Dysregulation in Cancer
Am. J. Pathol., October 1, 2009; 175(4): 1353 - 1361.
[Abstract] [Full Text] [PDF]


Home page
BloodHome page
W. Fiskus, Y. Wang, A. Sreekumar, K. M. Buckley, H. Shi, A. Jillella, C. Ustun, R. Rao, P. Fernandez, J. Chen, et al.
Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
Blood, September 24, 2009; 114(13): 2733 - 2743.
[Abstract] [Full Text] [PDF]


Home page
Mol Cancer ResHome page
B. D.W. Karanikolas, M. L. Figueiredo, and L. Wu
Polycomb Group Protein Enhancer of Zeste 2 Is an Oncogene That Promotes the Neoplastic Transformation of a Benign Prostatic Epithelial Cell Line
Mol. Cancer Res., September 1, 2009; 7(9): 1456 - 1465.
[Abstract] [Full Text] [PDF]


Home page
JNCI J Natl Cancer InstHome page
B. E. G. Rothberg, M. B. Bracken, and D. L. Rimm
Tissue Biomarkers for Prognosis in Cutaneous Melanoma: A Systematic Review and Meta-analysis
J Natl Cancer Inst, April 1, 2009; 101(7): 452 - 474.
[Abstract] [Full Text] [PDF]


Home page
ScienceHome page
S. Varambally, Q. Cao, R.-S. Mani, S. Shankar, X. Wang, B. Ateeq, B. Laxman, X. Cao, X. Jing, K. Ramnarayanan, et al.
Genomic Loss of microRNA-101 Leads to Overexpression of Histone Methyltransferase EZH2 in Cancer
Science, December 12, 2008; 322(5908): 1695 - 1699.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
S. Fujii, K. Ito, Y. Ito, and A. Ochiai
Enhancer of Zeste Homologue 2 (EZH2) Down-regulates RUNX3 by Increasing Histone H3 Methylation
J. Biol. Chem., June 20, 2008; 283(25): 17324 - 17332.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Pathol.Home page
H Vekony, F M Raaphorst, A P Otte, M van Lohuizen, C R Leemans, I van der Waal, and E Bloemena
High expression of Polycomb group protein EZH2 predicts poor survival in salivary gland adenoid cystic carcinoma
J. Clin. Pathol., June 1, 2008; 61(6): 744 - 749.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Nishikawa, M. Toyota, H. Suzuki, T. Honma, T. Fujikane, T. Ohmura, T. Nishidate, M. Ohe-Toyota, R. Maruyama, T. Sonoda, et al.
Gene Amplification and Overexpression of PRDM14 in Breast Cancers
Cancer Res., October 15, 2007; 67(20): 9649 - 9657.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
A. Miremadi, M. Z. Oestergaard, P. D.P. Pharoah, and C. Caldas
Cancer genetics of epigenetic genes
Hum. Mol. Genet., April 15, 2007; 16(R1): R28 - R49.
[Abstract] [Full Text] [PDF]


Home page
Hum Mol GenetHome page
S. J. Clark
Action at a distance: epigenetic silencing of large chromosomal regions in carcinogenesis
Hum. Mol. Genet., April 15, 2007; 16(R1): R88 - R95.
[Abstract] [Full Text] [PDF]


Home page
Genes Dev.Home page
A. H. Ting, K. M. McGarvey, and S. B. Baylin
The cancer epigenome--components and functional correlates
Genes & Dev., December 1, 2006; 20(23): 3215 - 3231.
[Abstract] [Full Text] [PDF]


Home page
Molecular Cancer TherapeuticsHome page
W. Fiskus, M. Pranpat, M. Balasis, B. Herger, R. Rao, A. Chinnaiyan, P. Atadja, and K. Bhalla
Histone deacetylase inhibitors deplete enhancer of zeste 2 and associated polycomb repressive complex 2 proteins in human acute leukemia cells
Mol. Cancer Ther., December 1, 2006; 5(12): 3096 - 3104.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
L. Ding and C. G. Kleer
Enhancer of Zeste 2 as a Marker of Preneoplastic Progression in the Breast
Cancer Res., October 1, 2006; 66(19): 9352 - 9355.
[Abstract] [Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2006 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online